| scholarly article | Q13442814 |
| P2093 | author name string | Frederick W Holtsberg | |
| Charles Mark Ensor | |||
| John S Bomalaski | |||
| Mike A Clark | |||
| P433 | issue | 19 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5443-5450 | |
| P577 | publication date | 2002-10-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo | |
| P478 | volume | 62 |
| Q41197125 | A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients |
| Q90121775 | A bioengineered arginine-depleting enzyme as a long-lasting therapeutic agent against cancer |
| Q30393023 | A broader view: microbial enzymes and their relevance in industries, medicine, and beyond. |
| Q94470572 | A modified arginine-depleting enzyme NEI-01 inhibits growth of pancreatic cancer cells |
| Q36557480 | A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma. |
| Q89414205 | A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies |
| Q34250146 | A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients |
| Q38848537 | Advanced Hepatocellular Cancer: the Current State of Future Research |
| Q38961789 | Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. |
| Q36869275 | An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo |
| Q50143099 | Arginase: A Multifaceted Enzyme Important in Health and Disease. |
| Q26765461 | Arginine Metabolism in Bacterial Pathogenesis and Cancer Therapy |
| Q39146030 | Arginine Metabolism in Myeloid Cells Shapes Innate and Adaptive Immunity |
| Q35682009 | Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase |
| Q37068792 | Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis |
| Q34305783 | Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling |
| Q38816145 | Arginine dependence of tumor cells: targeting a chink in cancer's armor |
| Q37160927 | Arginine deprivation as a targeted therapy for cancer |
| Q24634269 | Arginine deprivation therapy for malignant melanoma |
| Q37748811 | Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma |
| Q38602768 | Arginine deprivation, growth inhibition and tumour cell death: 3. Deficient utilisation of citrulline by malignant cells |
| Q94544273 | Arginine deprivation: a potential therapeutic for cancer cell metastasis? A review |
| Q34497105 | Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. |
| Q34314481 | Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy |
| Q42293391 | Argininosuccinate Synthase 1-Deficiency Enhances the Cell Sensitivity to Arginine through Decreased DEPTOR Expression in Endometrial Cancer |
| Q50981834 | Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells. |
| Q33708112 | Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53 |
| Q24620561 | Argininosuccinate synthase: at the center of arginine metabolism |
| Q35535519 | Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy |
| Q35556985 | Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines. |
| Q37687381 | Co-application of canavanine and irradiation uncouples anticancer potential of arginine deprivation from citrulline availability |
| Q84230581 | Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients |
| Q41850297 | Deprivation of arginine by recombinant human arginase in prostate cancer cells |
| Q90665359 | Dietary modifications for enhanced cancer therapy |
| Q36873800 | Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas. |
| Q35233239 | Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy. |
| Q38657061 | Drug-induced amino acid deprivation as strategy for cancer therapy |
| Q60044945 | Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM |
| Q36586507 | Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. |
| Q39874016 | Expression of arginine deiminase from Pseudomonas plecoglossicida CGMCC2039 in Escherichia coli and its anti-tumor activity |
| Q37146591 | Factors affecting the clearance and biodistribution of polymeric nanoparticles. |
| Q40202441 | Genetic variation in SLC7A2 interacts with calcium and magnesium intakes in modulating the risk of colorectal polyps |
| Q28484452 | Hybrid sequencing approach applied to human fecal metagenomic clone libraries revealed clones with potential biotechnological applications |
| Q34626077 | Increased expression of argininosuccinate synthetase protein predicts poor prognosis in human gastric cancer |
| Q44565671 | L-arginine biosensors: A comprehensive review |
| Q92523787 | MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion |
| Q33844916 | Metabolomic Profiling of the Synergistic Effects of Melittin in Combination with Cisplatin on Ovarian Cancer Cells |
| Q39441390 | Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap. |
| Q35927116 | Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase |
| Q26740187 | Novel drugs that target the metabolic reprogramming in renal cell cancer |
| Q31139529 | Overexpression of arginine transporter CAT-1 is associated with accumulation of L-arginine and cell growth in human colorectal cancer tissue |
| Q28288793 | Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase |
| Q38929570 | Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer |
| Q34911774 | Pegylated arginine deiminase: a novel anticancer enzyme agent |
| Q41779635 | Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (H |
| Q35674875 | Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors |
| Q34213639 | Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma |
| Q38718929 | Prevention and treatment of cancers by immune modulating nutrients. |
| Q64068982 | Prognostic Implications of Arginase and Cytokeratin 19 Expression in Hepatocellular Carcinoma After Curative Hepatectomy: Correlation With Recurrence-Free Survival |
| Q34832425 | RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells |
| Q42323682 | Reduced expression of ASS is closely related to clinicopathological features and post-resectional survival of hepatocellular carcinoma |
| Q34318551 | SCHEMA-designed variants of human Arginase I and II reveal sequence elements important to stability and catalysis |
| Q35803555 | Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy |
| Q61798869 | Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity |
| Q99555096 | Systemic Immunometabolism: Challenges and Opportunities |
| Q33593213 | Systemic therapy for advanced hepatocellular carcinoma: an update |
| Q37167357 | TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation |
| Q38181070 | Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges |
| Q35742521 | Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin |
| Q92573701 | Targeting extracellular nutrient dependencies of cancer cells |
| Q36468964 | The Emerging Hallmarks of Cancer Metabolism |
| Q40188863 | The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma |
| Q35889790 | The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells |
| Q36473355 | Therapeutic interventions to disrupt the protein synthetic machinery in melanoma |
Search more.